))
Episode 22. Management of Low-Risk MDS
Manage episode 363911680 series 3369804
İçerik Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:
1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/
3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/
4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008
5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/
6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034
7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892
8. Lenalidomide in MDS:
https://ascopubs.org/doi/10.1200/JCO.2015.66.0118
https://pubmed.ncbi.nlm.nih.gov/21753188/
9.Iron chelation therapy in MDS:
https://pubmed.ncbi.nlm.nih.gov/32203980/
47 bölüm
Paylaş
